AstraZeneca (AZN)

Sector:

Pharma and Biotech

Index:

FTSE 100

11,226.00p
   
  • Change Today:
    -190.00p
  • 52 Week High: 13,276.00p
  • 52 Week Low: 9,725.00p
  • Currency: UK Pounds
  • Shares Issued: 1,550.61m
  • Volume: 133,423
  • Market Cap: £174,071m
  • RiskGrade: 123

Financial Analysis

Select chart: EPS | Dividend | Revenue

Key Fundamentals

Year Ending Revenue ($m) Pre-tax ($m) EPS P/E PEG EPS Grth. Div Yield
31-Dec-20 26,617.00 3,916.00 244.00¢ 38.8 0.3 +137% 280.00¢ 3.0%
31-Dec-21 37,417.00 (265.00) 8.00¢ 1,403.3 n/a -97% 287.00¢ 2.6%
31-Dec-22 44,351.00 2,501.00 212.00¢ 68.5 0.0 +2,550% 290.00¢ 2.0%
31-Dec-23 45,811.00 6,899.00 726.00¢ 18.9 0.1 +242% 290.00¢ 2.1%
31-Dec-24 54,073.00 8,691.00 821.00¢ 16.5 1.3 +13% 310.00¢ 2.3%

a. Based on UK GAAP presentation of accounts - includes discontinued activities

Forecasts

Year Ending Revenue (£m) Pre-tax (£m) EPS P/E PEG EPS Grth. Div Yield
31-Dec-25 57,176.50 17,894.66 693.85p 16.5 1.8 +9% 251.79p 0.0%
31-Dec-26 60,621.81 20,010.44 781.99p 14.6 1.1 +13% 264.00p 0.0%

Copyright © 2025 FactSet Research Systems Inc. All rights reserved.

Price / Earnings Data

5 Yr High 5 Yr Low 5 Yr Avg Curr / Avg
Latest 41.01 15.96 321.31 0.06

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

Note 3: Above ratios are on a 'per annum' basis, adjusted for corporate actions and based on the fundamentals of the primary listed security.

Note 4: Under IFRS, all figures are based on 'Continuing' operations unless otherwise stated.

Note 5: In the case of dual listed securities, broker recommendations and forecasts relate to the primary listing.

Note 6: Forecast figures based on normalised accounts.

 

IFRS Changes - Find Out More

Find out about IFRS and how this affects the financial infomation for all UK companies.

AstraZeneca Market Data

Currency UK Pounds
Share Price 11,226.00p
Change Today -190.00p
% Change -1.66 %
52 Week High 13,276.00p
52 Week Low 9,725.00p
Volume 133,423
Shares Issued 1,550.61m
Market Cap £174,071m
RiskGrade 123

AstraZeneca Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
93.34% below the market average93.34% below the market average93.34% below the market average93.34% below the market average93.34% below the market average
87.23% below the sector average87.23% below the sector average87.23% below the sector average87.23% below the sector average87.23% below the sector average
Price Trend
41.51% above the market average41.51% above the market average41.51% above the market average41.51% above the market average41.51% above the market average
51.02% above the sector average51.02% above the sector average51.02% above the sector average51.02% above the sector average51.02% above the sector average
Income
65.81% below the market average65.81% below the market average65.81% below the market average65.81% below the market average65.81% below the market average
14.29% above the sector average14.29% above the sector average14.29% above the sector average14.29% above the sector average14.29% above the sector average
Growth
85.34% above the market average85.34% above the market average85.34% above the market average85.34% above the market average85.34% above the market average
100.00% above the sector average100.00% above the sector average100.00% above the sector average100.00% above the sector average100.00% above the sector average

What The Brokers Say

Strong Buy 10
Buy 15
Neutral 4
Sell 0
Strong Sell 0
Total 29
buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

AstraZeneca Dividends

  Latest Previous
  2nd Interim 1st Interim
Ex-Div 20-Feb-25 08-Aug-24
Paid 24-Mar-25 09-Sep-24
Amount 210.00¢ 100.00¢

Trades for 31-Mar-2025

Time Volume / Share Price
11:43 39 @ 11,226.00p
11:43 17 @ 11,228.00p
11:43 1 @ 11,228.00p
11:43 41 @ 11,230.00p
11:43 37 @ 11,230.00p

AstraZeneca Key Personnel

Chair Michel Demare

Top of Page